More pertinent point here is Roche have another late stage clinical failure on their hands.
Add the crappy Sarepta gene therapy results...it hasn't been a great 3 months for them.
2020 was not a good year for Big Pharma to build pipeline.
I can feel a 'partnership' or strategic investment is just around the corner for ANP, Pharma need pipeline and reading the Biotech pundits, it appears M&A will increase in 2021.
ANP Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
